PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors

PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this setting, accumulation of DNA damage leads to cell death. Because increased DNA damage and subsequent immune activation can prime an anti-tumor immune response, we studied the impact of olaparib ± immune checkpoint blockade...

Full description

Bibliographic Details
Main Authors: Anna D. Staniszewska, Joshua Armenia, Matthew King, Chrysiis Michaloglou, Avinash Reddy, Maneesh Singh, Maryann San Martin, Laura Prickett, Zena Wilson, Theresa Proia, Deanna Russell, Morgan Thomas, Oona Delpuech, Mark J. O’Connor, Elisabetta Leo, Helen Angell, Viia Valge-Archer
Format: Article
Language:English
Published: Taylor & Francis Group 2022-12-01
Series:OncoImmunology
Subjects:
PARP inhibitor
olaparib
cGAS-STING
immune checkpoint blockade
BRCA
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2022.2083755

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2022.2083755

Similar Items